Loading...

NEXTGEN CML PANEL

image not found

NABL Cap Accredited 
The NextGen CML Panel at Metropolis Healthcare is an advanced molecular test designed to identify key genetic mutations associated with Chronic Myeloid Leukemia (CML). Using high-depth Next-Generation Sequencing, this panel detects both common and rare variants that influence disease behavior, treatment response, and prognosis. Metropolis Healthcare ensures precise mutation profiling through robust sequencing and expert interpretation. This test is recommended for newly diagnosed CML patients or those requiring deeper molecular insights for treatment planning. Early mutation detection supports personalized therapy and improved clinical outcomes.

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 21,000.00

Sample Type: EDTA Whole Blood

Fasting Not Required


Notes:N8189

Frequently Asked Questions (FAQ's):

What does the NextGen CML Panel at Metropolis Healthcare include?
It analyzes genes associated with CML progression and therapy resistance, providing a detailed molecular profile.

How does Metropolis Healthcare perform this CML gene panel?
Metropolis Healthcare uses high-coverage Next-Generation Sequencing along with expert bioinformatics to identify clinically relevant mutations.

Who should take the NextGen CML Panel at Metropolis Healthcare?
Newly diagnosed CML patients or those showing inadequate response to therapy should consider this advanced genetic evaluation.

Is fasting required for this molecular CML test at Metropolis Healthcare?
No, fasting is not required; the test is performed on a blood or bone marrow sample.

How long do results take at Metropolis Healthcare?
Results usually take 2–3 weeks due to the detailed sequencing and interpretation process.

Can this test at Metropolis Healthcare help guide CML treatment?
Yes, the results help clinicians choose targeted therapies and monitor treatment effectiveness more accurately.

How accurate is the NGS technology used for this panel at Metropolis Healthcare?
Metropolis Healthcare ensures high accuracy with deep sequencing coverage and stringent quality measures.

Can this test detect resistance mutations at Metropolis Healthcare?
Yes, it identifies mutations that may cause resistance to tyrosine kinase inhibitors, helping refine treatment strategies.

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab